Health
Canadian dentists desperate for details on federal dental care plan
News release from Canada’s Provincial and Territorial Dental Associations
Canadian dentists to MPs: We need answers about the Canadian Dental Care Plan
Lack of consultation with provincial and territorial dental associations is worrying
There are only two months left before the Canadian Dental Care Plan (CDCP) becomes available to many more Canadians. Yet more than 25,000 dentists nationwide are in the dark about how the Government of Canada will safeguard access to dental care.
In a letter sent to Members of Parliament (MPs) this week, the presidents of provincial and territorial dental associations across the country asked how the government will:
- Safeguard employer-provided dental plans that two-thirds of Canadians currently have access to?
- Ensure that a strong federal program can be coordinated with existing provincial programs?
- Protect patient choice and maintain the patient-provider relationship?
- Ensure minimal, efficient administration that promotes timely access to care?
- Respect the costs of delivering dental care to maximize provider participation?
- Increase the number of dental assistants and dental hygienists to meet the demands of the CDCP?
Dentists want to champion a CDCP that will respect patients, providers, and taxpayers. The provincial and territorial dental associations are concerned that the CDCP has been compromised by a lack of meaningful consultation with dentists – who will be expected to deliver on the government’s promises.
The CDCP is currently in final planning stages, with a potential rollout in 2024 that will attempt to increase access to uninsured Canadians under 18, people with disabilities, and seniors who have an annual family income of less than $90,000. Dentists believe all Canadians need access to dental care. If not done properly, two-thirds of Canadians who have great employer-provided dental plans could lose their coverage and be forced into a worse plan. Costs would then skyrocket, which means the $13 billion over five years the government set aside would not be enough to sustain the plan.
Let’s take the time to get it right. We can increase access to dental care right now through an expansion of the interim measure already in place – the Canada Dental Benefit. This establishes a fixed dollar amount that a patient can use to be reimbursed for dental-related expenses.
Facts:
- Canada’s provincial and territorial dental associations represent more than 25,000 licensed dentists working in more than 16,000 offices. They treat more than 30 million Canadians every year and employ at least 50,0001 oral health care workers.
- Over 60 per cent of Canadians have a dentist they visit on a regular basis.2
- A recent survey commissioned by Health Canada found that nearly nine out 10 Canadians are satisfied with the Canada Dental Benefit.3
Quotes:
“To succeed, this plan needs to work for both patients and providers, and to work in each province. What we are recommending is based on decades of experience and caring for the oral health needs of the more than 30 million people that come into our dental offices across the country every year.” — Dr. Bruce Yaholnitsky, President, Alberta Dental Association
“Poorly designed programs do not improve access to care, and they leave the most vulnerable people in society behind. This is an historic opportunity, but only if the government gets it right. Dentists have the expertise, experience, and skills to know what it takes to ensure good oral and overall health.” — Dr. Rob Wolanski, President, British Columbia Dental Association
“As dentists we are excited to be a part of this Canadian dental care program, but there are key critical issues that need to be included for this program to be successful.” — Dr. Scott Leckie, President, Manitoba Dental Association
“New Brunswick dentists are already extremely busy with the recent spike in population and the backlog in demand for services related to Covid-19. This program was intended to provide dental care to the 35 per cent of Canadians who are uninsured. It needs to be easy to understand and to administer, and to be fair to all parties, including patients, dental care providers and taxpayers. Canadians need to know what benefits are being provided and which are not, before they arrive at the dental clinic.” — Dr. Joanah Campbell, President, New Brunswick Dental Society
“The new program must be sustainable in terms of funding, and easy to understand and access. It has to be patient-centred and work for everyone.” — Dr. Shane Roberts, President, Newfoundland & Labrador Dental Association
“While the CDCP has the potential to improve the lives of many Canadians, this can only be achieved if it’s done right. To ensure the greatest possible outcome, we must consider all of the moving pieces and take a patient-centred approach.” — Dr. Juli Waterbury, President, Nova Scotia Dental Association
“The CDCP could be a game-changer for Canadians’ access to dental care. But we have one chance to get it right. Here in Ontario, we have seen that dental care programs developed without the input of dentists are doomed to fail. Just look at the Ontario Seniors Dental Care Program, where waiting lists are up to two years long in some areas, and some patients have to travel ridiculously long distances to receive treatment.” — Dr. Brock Nicolucci, President, Ontario Dental Association
“This new program has the potential to improve access to care for many Canadians. It must be sustainable, patient-centred, and easy to access for patients. A poorly designed program will not improve access to care which is something we would like to avoid. We want this to work for Canadians.” — Dr. Derek Thiessen, President, College of Dental Surgeons of Saskatchewan
Health
The Data That Doesn’t Exist
ACIP voted to un-recommend the Hep B birth dose, but here’s the problem: they still can’t weigh the other side of the ledger
Sunday, something happened that has never happened in the history of American public health: ACIP voted 8-3 to un-recommend the universal birth dose of hepatitis B for babies born to mothers who test negative for the virus. After 34 years of jabbing every American newborn within hours of taking their first breath—regardless of whether their mother had hepatitis B—the committee finally acknowledged what 25 European countries figured out decades ago: it doesn’t make sense.
But watching this vote unfold, I couldn’t help but notice the absurdity of the debate itself. Committee members who opposed the change kept saying variations of the same thing: “We’ve heard ‘do no harm’ as a moral imperative. We are doing harm by changing this wording.” Another said “no rational science has been presented” to support the change.
How to End the Autism Epidemic is a reader-supported publication.
To receive new posts and support my work, consider becoming a free or paid subscriber.
And therein lies the fundamental problem with ACIP—and with the entire vaccine regulatory apparatus in America. They literally cannot weigh risk versus benefit because they only have data on one side of the scale.
The Missing Side of the Ledger
When ACIP debates adding or removing a vaccine from the schedule, they can produce endless data on disease incidence. They can show you charts demonstrating how hepatitis B cases in infants dropped from thousands to single digits after 1991. They can model projected infections if vaccination rates decline. They have this data at their fingertips because tracking infectious disease is something our public health apparatus actually does.
But ask them to produce equivalent data on vaccine injury, and you’ll get silence. Not “the data shows injuries are rare.” Not “here’s our comprehensive tracking of adverse events.” Just… nothing. A void where information should be.
This is not an accident. This is by design.
The safety trials for Engerix-B and Recombivax HB—the two hepatitis B vaccines given to American newborns—monitored adverse events for four to five days after injection. That’s it. If your baby developed seizures on day six, or regressed into autism over the following months, or developed autoimmune disease in the following year—none of that would appear in the pre-licensure safety data.
And the post-market surveillance? VAERS is a voluntary reporting system that the CDC itself acknowledges captures only a tiny fraction of adverse events. A Harvard-funded study found it captures perhaps 1% of actual vaccine injuries. Vaccine court has paid out over $5 billion in claims while simultaneously being structured to make filing nearly impossible for average families.
So when Dr. Cody Meissner voted against removing the Hep B birth dose and said he saw “clear evidence of the benefits” but “not the harms,” he was accidentally revealing the entire rotten structure. Of course he doesn’t see the harms. Nobody is systematically looking for them.
The Invisibility of Vaccine Injury
Here’s what most people don’t understand about vaccine injury: it’s nothing like a gunshot wound.
If you shoot someone, the cause is obvious. There’s a bullet, a wound, blood, a clear mechanism of action visible to any observer. Even a medical examiner who’s never seen the victim before can determine cause of death.
Vaccine injury doesn’t work that way. When aluminum nanoparticles from a vaccine cross the blood-brain barrier via macrophages, when they lodge in brain tissue and trigger chronic neuroinflammation, when a child slowly regresses over weeks or months—there’s no bullet. There’s no smoking gun. There’s just a before and an after, and a desperate parent trying to explain to doctors that something changed.
This invisibility is the vaccine program’s greatest protection. Because the injury mechanism is complex and delayed, because it doesn’t leave an obvious wound, because it requires actually looking to find—and because no one in authority is looking—the injuries simply don’t exist in the official record.
I watched my own son Jamie regress after his vaccines. A healthy, developing toddler who lost his words, stopped making eye contact, and retreated into a world we couldn’t reach. My wife and I know what happened. Thousands of other parents know the same thing happened to their children. But because this type of injury doesn’t show up on a simple blood test, because there’s no autopsy finding that says “vaccine-induced encephalopathy,” ACIP members can sit in a room and say with straight faces that they don’t see evidence of harm.
They’re not lying. They literally can’t see it. Because no one is measuring it.
The Chicken Pox Conundrum
Here’s an example that illustrates the insanity of our current approach.
The varicella (chicken pox) vaccine was added to the schedule in 1995. It definitely reduces chicken pox cases. The data is clear on that front. Mission accomplished, right?
But what about the other side of the ledger?
Emerging research suggests that wild chicken pox infection provides some protective effect against brain cancers—particularly glioma, the most common type of primary brain tumor. Multiple studies have found that people who had chicken pox as children have significantly lower rates of brain cancer later in life. The hypothesis is that the immune response to wild varicella provides lasting immunological benefits that extend far beyond preventing itchy spots.
Meanwhile, the vaccine itself has been associated with increased rates of autoimmune conditions. Studies have linked varicella vaccination to higher rates of herpes zoster (shingles) outbreaks in younger age groups, to autoimmune disorders, to various adverse events that weren’t captured in the original short-term safety trials.
So what’s the true risk-benefit of the chicken pox vaccine? Does preventing a week of itchy discomfort in childhood justify potentially increased rates of brain cancer and autoimmune disease later in life?
ACIP can’t answer this question. They literally don’t have the data. They can show you chicken pox cases going down. They cannot show you a comprehensive analysis of long-term neurological and immunological outcomes in vaccinated versus unvaccinated populations, because that study has never been done.
And so they keep recommending the vaccine based on the only data they have—the disease prevention data—while remaining willfully blind to consequences they’ve never bothered to measure.
The ACIP Paradox
Sunday’s vote was historic, but it also revealed the fundamental paradox of vaccine regulation in America.
The committee members who voted to remove the universal Hep B birth dose recommendation did so largely based on comparative evidence from Europe, parental concerns, and the basic logic that vaccinating a 12-hour-old baby for a sexually transmitted disease their mother doesn’t have makes no medical sense. They were right to do so.
But the committee members who voted against the change weren’t wrong either, from their perspective. They looked at the only data they have—disease prevention data—and concluded that removing the recommendation could lead to more hepatitis B cases. And within their limited framework, they’re correct.
The problem is the framework itself.
True risk-benefit analysis requires data on both risks AND benefits. ACIP has comprehensive data on benefits (disease prevention) and virtually no data on risks (vaccine injury). So every decision they make is fundamentally flawed from the start.
When Dr. Joseph Hibbeln complained that “no rational science has been presented” to support changing the recommendations, he was inadvertently indicting the entire system. Of course no comprehensive vaccine injury data was presented—such data doesn’t exist because no one has been willing to collect it.
This is like asking someone to make an informed financial decision while only showing them potential profits and hiding all possible losses. Of course the decision will be skewed. Of course you’ll end up with a bloated portfolio of high-risk investments that look great on paper.
The Real Reform
If RFK Jr. and the new HHS leadership want to actually fix the vaccine program, they need to understand that removing individual vaccines or making them “optional” is just rearranging deck chairs on the Titanic.
The real reform is creating the data infrastructure that should have existed from the beginning.
We need a comprehensive, long-term, vaccinated-versus-unvaccinated health outcomes study. Not a five-day safety trial. A multi-decade tracking of neurological, immunological, and developmental outcomes across populations with varying vaccination status. Florida just eliminated all vaccine mandates—that state alone could provide the data we need within ten years if someone had the courage to actually collect it.
We need a vaccine injury surveillance system that actually captures adverse events. Not a voluntary reporting system that misses 99% of injuries. An active surveillance system with trained clinicians looking for the kinds of delayed, complex injuries that vaccines actually cause.
We need accountability for manufacturers. The 1986 National Childhood Vaccine Injury Act removed all liability from vaccine makers—and predictably, the vaccine schedule exploded afterward while safety research stagnated. Why would any company invest in safety when they can’t be sued for injuries?
Without this data, every ACIP meeting will be the same performance we watched this week: members confidently citing disease prevention data while admitting they can’t see evidence of harm—not because harm doesn’t exist, but because no one is looking for it.
What Comes Next
Sunday’s vote was a crack in the wall. For the first time, an American regulatory body acknowledged that perhaps vaccinating every newborn within hours of birth for a disease primarily transmitted through sex and IV drug use doesn’t make sense when the mother has already tested negative.
But the forces of institutional inertia are already mobilizing. The American Academy of Pediatrics is “disappointed.” The American Medical Association is calling for the CDC to reject the recommendation. The pharmaceutical industry—which collects over $225 million annually from Hep B birth doses alone—will fight to restore the universal recommendation.
They will cite the same data they always cite: disease prevention data. Cases prevented. Infections avoided. Lives saved—theoretically.
They will not cite vaccine injury data, because that data doesn’t exist in any comprehensive form. They will not present long-term health outcomes in vaccinated versus unvaccinated children, because those studies have been actively avoided for decades. They will not acknowledge the thousands of families who have watched their children regress after vaccination, because those injuries aren’t captured in any official database.
And this is why ACIP will always be hamstrung. Until we build the data infrastructure to actually measure vaccine injury—to put real numbers on the other side of the ledger—every vaccine decision will be based on incomplete information. Every “risk-benefit analysis” will be a fraud, because we’re only measuring half the equation.
The hepatitis B birth dose vote was a small victory. But the larger battle—for actual science, for complete data, for true informed consent—that battle is just beginning.
And until we win it, ACIP will continue making decisions in the dark, confidently citing evidence of benefits while remaining deliberately blind to the harms they’ve never bothered to measure.
About the author
J.B. Handley is the proud father of a child with Autism. He spent his career in the private equity industry and received his undergraduate degree with honors from Stanford University. His first book, How to End the Autism Epidemic, was published in September 2018. The book has sold more than 75,000 copies, was an NPD Bookscan and Publisher’s Weekly Bestseller, broke the Top 40 on Amazon, and has more than 1,000 Five-star reviews. Mr. Handley and his nonspeaking son are also the authors of Underestimated: An Autism Miracle and co-produced the film SPELLERS, available now on YouTube.
How to End the Autism Epidemic is a reader-supported publication.
To receive new posts and support my work, consider becoming a free or paid subscriber.
Health
CDC Vaccine Panel Votes to End Universal Hep B Vaccine for Newborns
“While I question whether any baby should receive a vaccine against a rare disease in infancy, I am pleased that this is now a matter for parents and their healthcare practitioner to decide — not a state mandate based on a federal pharma-backed recommendation.”
Advisers to the Centers for Disease Control and Prevention (CDC) have voted to end a decades-long recommendation that all infants born in the U.S. receive the hepatitis B vaccine (Hep B) within 12-24 hours of birth.
Instead, for babies born to mothers who test negative for hepatitis B, the committee recommends that families determine whether to give their child the Hep B shot at birth through individual decision-making with their physician.
For infants who don’t get the birth dose, the committee recommends the initial dose of the vaccine not be administered until infants are at least 2 months old.
Three of the 11 committee members — Dr. Raymond Pollack, Dr. Cody Meissner and Dr. Joseph R. Hibbeln — opposed the recommendation. The remaining eight members supported it.
Andrew Johnson from the Centers for Medicare & Medicaid Services assured the committee that the language change will not affect Medicaid or insurance coverage of the vaccine.
For mothers whose hepatitis B status is unknown or who test positive, the birth dose recommendation remains in place.
Children’s Health Defense CEO Mary Holland, a long-time critic of the universal birth dose policy, welcomed the committee’s vote to “end the ill-considered universal recommendation for the Hep B birth vaccine dose.”
Holland added:
“The science behind that universal recommendation was a sham, based on thoroughly inadequate clinical trials. Hundreds of babies unquestionably died because of it. While I question whether any baby should receive a vaccine against a rare disease in infancy, I am pleased that this is now a matter for parents and their healthcare practitioner to decide — not a state mandate based on a federal pharma-backed recommendation.
“And while the ACIP [Advisory Committee on Immunization Practices] debate on this issue was tedious and rancorous at times, it is an extremely positive change that actual debate about childhood vaccines is occurring in government venues with impact. This is the transparency that Secretary Kennedy promised.”
Dr. Monique Yohanan, senior fellow for health policy at Independent Women, told The Defender there was never “a good science-based reason to have a universal vaccination that 99% of babies born in the United States are not at any risk,” and that the vote was “good news for babies.”
She added that she hoped it would “provide an opportunity to actually have outreach to the moms who are positive for hepatitis B, women who are immigrants, women who are IV drug users.” She said the previous policy was “performative compassion. And these are really underserved women who we ignored the outreach that they needed.”
The committee also voted 6-4 with one abstention that after the initial Hep B shot, parents should consult with healthcare providers to consider whether their child should have a serology test, which would show whether they had antibodies considered sufficient to protect them against the disease.
The committee voted to update the CDC Vaccines for Children (VFC) Program funding to match ACIP’s recommendations. Several committee members, including Meissner and Hibbeln, abstained from voting on the VFC resolution, protesting that they didn’t understand the implications of the vote — reflecting some of the disagreement that pervaded the two-day meeting.
The votes on the Hep B vaccine were originally scheduled for the September meeting, but were deferred to allow the CDC work group to put together more data to inform the committee’s decision.
Sunday’s vote was postponed from Saturday so members could have more time to review the language of the proposal.
Like flying in a plane that wasn’t safety tested?
The decision to postpone followed a contentious day-long meeting on Thursday, during which some members of the committee and liaisons from professional associations argued there was no need to change the recommendation, because there was no “evidence of harm” from the vaccine.
Advocates for changing the recommendation pointed to a near-complete lack of safety data — small clinical trials for the vaccines tracked infants for a week or less after the shot and little follow-up research on autoimmune and neurological disorders.
Big differences of opinion persisted at Sunday’s meeting.
ACIP member Retsef Levi, Ph.D., said that for parents whose children were at extremely low risk, the decision to give them the vaccine was analogous to flying in a plane — they wouldn’t get in a plane that hadn’t been safety tested, why should they give their child a vaccine that hadn’t been safety tested.
Meissner disagreed, saying, “We know vaccines are safe. There is no question that the COVID vaccine recommendations were dishonest, disingenuous, but the hepatitis B vaccine is very well established.”
In opening remarks, Dr. Robert Malone — who chaired the meeting because the newly named committee chairperson, Dr. Kirk Milhoun, is traveling — said “the credibility of the ACIP rests not on speed, but on rigor.”
Commenting on the heated discussions during Thursday’s meeting, Milhoun said that scientific debates are necessarily contentious.
“If they are not contentious, if they are not approached with rigor, then we end up with bad decisions. We end up with bad science. We must actively engage in responsible debate concerning contentious issues. We must boldly address change, risk new ideas, and conflicting hypotheses, which is the proper nature of evidence-based science.”
Dr. Jason Goldman, a liaison to the ACIP for the American College of Physicians, attacked opposing viewpoints as unscientific. Goldman said the Hep B vaccine discussion was “an unnecessary solution looking for a problem.”
‘If adults won’t go for the shots, then give them to babies’
The Hep B vaccine has been universally recommended for infants since 1991. The first shot is currently given within 24 hours after birth to prevent infection with hepatitis B from mothers who carry the disease — less than 0.5% of mothers.
Mothers can be tested in the hospital to determine whether they have the disease, and current tests have a 100% accuracy rate, according to FDA ex officio ACIP participant Tracy Beth Høeg, M.D., Ph.D.
However, a 1991 New York Times article posted on Substack yesterday by Dr. Meryl Nass showed that when the universal shot was rolled out, the goal was not to prevent maternal transmission — the goal was to prevent adult cases, at a time when adult cases were deemed a national crisis. However, adults commonly didn’t get the shot.
“If adults won’t go for the shots, then give them to babies,” the article said.
Following Thursday’s meeting, legacy media attacked the committee and the CDC’s presenters and highlighted charges of misinformation by liaison members. Liaisons are nonvoting members from professional medical organizations who can offer their opinions and advice to the committee.
Representatives from some of those groups, including the American Academy of Pediatrics (AAP) and the American Medical Association, were disinvited in August from participation in the workgroups due to conflicts of interest.
Since then, the AAP has boycotted the ACIP meetings
At the start of today’s meeting, Meissner castigated AAP for this move. He said he was concerned that by not participating, they would be seen as being more focused on making a political statement than attending to the health of children.
He said that pediatricians should be part of the discussions. “Refusal to participate in the ACIP meetings does not appear to be in the best interest of children.”
Immediately following today’s vote, the Times quoted “experts” from some of the staunchest advocates for all vaccines on the childhood schedule, such as the director of the Center for Infectious Disease Research & Policy, Michael Osterholm, Ph.D., saying that the vote shows federal health authorities can no longer be trusted.
Osterholm, a member of the COVID-19 Advisory Board under the Biden administration, is one of the key players in the “Vaccine Integrity Project,” funded by iAlumbra, a nonprofit founded by Walmart heiress and philanthropist Christy Walton. The project plans to make its own vaccine recommendations.
This Substack is reader-supported.
To receive new posts and support my work, consider becoming a free or paid subscriber.
Vaccine recommendations ‘should not be treated as mandates’
During the day-and-a-half-long discussion about the Hep B vaccine, several committee members, including Dr. Evelyn Griffin, raised concerns that the birth recommendation posed challenges for informed consent, because mothers who had just delivered babies were not in a position to calmly evaluate risks and benefits.
Others, including Levi, argued that the vaccine requirements for children to attend school effectively functioned as mandates.
Liaison members universally disagreed that the recommendations were mandates and argued that ACIP recommendations were really only recommendations, and parents could do what they wanted.
CDC ex officio member, Dr. Adam Langer, who was opposed to changing the recommendation, said that the recommendations had come to function as mandates, but that was not the intention. He proposed the committee make a formal statement that “all vaccine recommendations are recommendations. They should not be treated as mandates.”
He added that mandates put in place by state and local jurisdictions were “problematic.”
“We have a lot of challenges with our culture and our traditions in this country, with telling people what they must and must not do. But that’s not what we’re saying here. We’re saying that at the population level, in the majority of cases, this is what the sign shows is the best practice.”
He said providers should always make the best decision for the individual patient they are working with. “That’s the reason why you’ve been entrusted with a license to practice medicine.”
Watch the ACIP meeting here:
-
Business2 days agoWhy Does Canada “Lead” the World in Funding Racist Indoctrination?
-
Business2 days agoLoblaws Owes Canadians Up to $500 Million in “Secret” Bread Cash
-
Focal Points1 day agoCommon Vaccines Linked to 38-50% Increased Risk of Dementia and Alzheimer’s
-
Business20 hours agoThe EU Insists Its X Fine Isn’t About Censorship. Here’s Why It Is.
-
Dan McTeague2 days agoWill this deal actually build a pipeline in Canada?
-
Economy16 hours agoAffordable housing out of reach everywhere in Canada
-
Media2 days agoThey know they are lying, we know they are lying and they know we know but the lies continue
-
Censorship Industrial Complex2 days agoUS Condemns EU Censorship Pressure, Defends X




